The MS Trust is very disappointed that the Scottish Medicines Consortium is unable to recommend ocrelizumab as an NHS treatment for relapsing remitting MS.
- Ocrelizumab not approved for PPMS
- Solvents, smoking and MS risk
- Air pollutants not linked to MS
- Cannabis review finds benefits
The combination of exposure to chemical solvents at work, having genes associated with MS and smoking greatly increases the risk of developing multiple sclerosis according to new research.
The MS Trust is very disappointed that NICE is unable to recommend ocrelizumab as an NHS treatment for early primary progressive MS.
NICE has approved ocrelizumab (Ocrevus) as a treatment for relapsing remitting multiple sclerosis on the NHS in England and Wales.
- NICE say yes to Ocrevus for RRMS
- Review of medical cannabis
- PIP review changes
- Tysabri in SPMS
- Stress linked to MS risk
On September 5, 2017, the MS Trust announced that it would be working with NHS Lanarkshire to improve access to MS nurses in the area, and ensure people living with MS get the support they need. Nine months on, we're pleased to report on the positive difference the new MS nurses have made to people with MS in Lanarkshire.
- School project explores MS
- Tecfidera and Gilenya compared
- Ocrevus delays progression
- Ocrevus in PPMS - new trial announced
- Obesity and smoking and risk of MS
- Family support helps